Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration

Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentr...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 59; no. 2; p. 2100185
Main Authors Morrison, Cameron B., Shaffer, Kendall M., Araba, Kenza C., Markovetz, Matthew R., Wykoff, Jason A., Quinney, Nancy L., Hao, Shuyu, Delion, Martial F., Flen, Alexis L., Morton, Lisa C., Liao, Jimmy, Hill, David B., Drumm, Mitchell L., O'Neal, Wanda K., Kesimer, Mehmet, Gentzsch, Martina, Ehre, Camille
Format Journal Article
LanguageEnglish
Published England 01.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown. We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties. Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO , normalised mucus recovery to modulator-treated cell levels. These results indicate that airway dehydration, not acidic pH and/or low [HCO ], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.
AbstractList Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction (i.e. acidic airway surface liquid (ASL) pH, low bicarbonate (HCO3 -) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.QUESTIONCystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction (i.e. acidic airway surface liquid (ASL) pH, low bicarbonate (HCO3 -) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.MATERIALS/METHODSWe characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO3 -, normalised mucus recovery to modulator-treated cell levels.RESULTSLoss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO3 -, normalised mucus recovery to modulator-treated cell levels.These results indicate that airway dehydration, not acidic pH and/or low [HCO3 -], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.CONCLUSIONThese results indicate that airway dehydration, not acidic pH and/or low [HCO3 -], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.
Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown. We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties. Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO , normalised mucus recovery to modulator-treated cell levels. These results indicate that airway dehydration, not acidic pH and/or low [HCO ], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.
Author Morton, Lisa C.
Shaffer, Kendall M.
O'Neal, Wanda K.
Morrison, Cameron B.
Araba, Kenza C.
Quinney, Nancy L.
Delion, Martial F.
Markovetz, Matthew R.
Ehre, Camille
Gentzsch, Martina
Wykoff, Jason A.
Drumm, Mitchell L.
Hao, Shuyu
Hill, David B.
Flen, Alexis L.
Liao, Jimmy
Kesimer, Mehmet
AuthorAffiliation 3 Department of Physics and Astronomy, The University of North Carolina at Chapel Hill
2 Division of Pediatric Pulmonology, The University of North Carolina at Chapel Hill
5 Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill
1 Marsico Lung Institute / CF Center, The University of North Carolina at Chapel Hill
4 Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine
AuthorAffiliation_xml – name: 4 Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine
– name: 5 Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill
– name: 1 Marsico Lung Institute / CF Center, The University of North Carolina at Chapel Hill
– name: 3 Department of Physics and Astronomy, The University of North Carolina at Chapel Hill
– name: 2 Division of Pediatric Pulmonology, The University of North Carolina at Chapel Hill
Author_xml – sequence: 1
  givenname: Cameron B.
  orcidid: 0000-0002-4031-9521
  surname: Morrison
  fullname: Morrison, Cameron B.
– sequence: 2
  givenname: Kendall M.
  surname: Shaffer
  fullname: Shaffer, Kendall M.
– sequence: 3
  givenname: Kenza C.
  surname: Araba
  fullname: Araba, Kenza C.
– sequence: 4
  givenname: Matthew R.
  surname: Markovetz
  fullname: Markovetz, Matthew R.
– sequence: 5
  givenname: Jason A.
  surname: Wykoff
  fullname: Wykoff, Jason A.
– sequence: 6
  givenname: Nancy L.
  surname: Quinney
  fullname: Quinney, Nancy L.
– sequence: 7
  givenname: Shuyu
  surname: Hao
  fullname: Hao, Shuyu
– sequence: 8
  givenname: Martial F.
  surname: Delion
  fullname: Delion, Martial F.
– sequence: 9
  givenname: Alexis L.
  surname: Flen
  fullname: Flen, Alexis L.
– sequence: 10
  givenname: Lisa C.
  surname: Morton
  fullname: Morton, Lisa C.
– sequence: 11
  givenname: Jimmy
  surname: Liao
  fullname: Liao, Jimmy
– sequence: 12
  givenname: David B.
  surname: Hill
  fullname: Hill, David B.
– sequence: 13
  givenname: Mitchell L.
  surname: Drumm
  fullname: Drumm, Mitchell L.
– sequence: 14
  givenname: Wanda K.
  surname: O'Neal
  fullname: O'Neal, Wanda K.
– sequence: 15
  givenname: Mehmet
  surname: Kesimer
  fullname: Kesimer, Mehmet
– sequence: 16
  givenname: Martina
  surname: Gentzsch
  fullname: Gentzsch, Martina
– sequence: 17
  givenname: Camille
  surname: Ehre
  fullname: Ehre, Camille
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34172469$$D View this record in MEDLINE/PubMed
BookMark eNp9UU1r3DAQFSWh2Wz6CwpBx16cSpYsS5dAWZoPCBTK3oVWHnVVbGsjyRv231dOsqXJoaeBmffBvHeOTsYwAkKfKbmiVLKvlCnFCGFXhFDZVDWp6Qe0mLfVvD5BC6IIq6hi4gydp_S74ARn9CM6Y5y2NRdqgcI6gskDjBkHh-0hZW-x85sYkk_Y-PhkDthC3yf85PMWr27WP_EQuqk3OcSEI-whJijQDcRoisww2SnhXQw7iNmXy94bvD100WQfxgt06kyf4NPrXKL1zff16q56-HF7v_r2UFkmSK6AsM42RLTcKSvVxkFjhZCidq0zjAtGW24kEVwJZVtGlLAdCCs54a4GwZbo-kV2N20G6Gz5L5pe76IfTDzoYLx-exn9Vv8Key1loySlReDLq0AMjxOkrAef5hzMCGFKum5406i2LkUs0eW_Xn9NjiEXgHoB2JJqiuC09fk5jWLte02JngvVx0L1c6F6LrRw2TvuUf5_rD9bI6TN
CitedBy_id crossref_primary_10_1080_17476348_2022_2100350
crossref_primary_10_1093_pnasnexus_pgae390
crossref_primary_10_1016_j_jcf_2024_10_001
crossref_primary_10_1073_pnas_2313089121
crossref_primary_10_1073_pnas_2119680119
crossref_primary_10_1152_ajplung_00390_2022
crossref_primary_10_1186_s12931_024_03029_0
crossref_primary_10_1183_16000617_0068_2024
crossref_primary_10_3389_fphys_2022_884166
crossref_primary_10_2174_011573398X264594231027110541
crossref_primary_10_1126_scitranslmed_abl6328
crossref_primary_10_3390_ijms231911396
crossref_primary_10_3389_fphar_2023_1158207
crossref_primary_10_3390_cells12182208
crossref_primary_10_1002_ppul_26261
crossref_primary_10_1016_j_ejrad_2022_110421
crossref_primary_10_1111_bph_16417
crossref_primary_10_1038_s41598_024_66510_2
crossref_primary_10_1063_5_0187974
crossref_primary_10_3390_ijms24055010
crossref_primary_10_1186_s12931_023_02612_1
crossref_primary_10_7554_eLife_75871
crossref_primary_10_1002_bit_28754
crossref_primary_10_3389_fcimb_2022_969326
crossref_primary_10_1038_s41572_024_00538_6
crossref_primary_10_3390_cells12222618
crossref_primary_10_3389_fphys_2023_1111647
crossref_primary_10_3390_ijms25031933
crossref_primary_10_1007_s00424_024_02937_w
crossref_primary_10_1073_pnas_2118126119
crossref_primary_10_1002_advs_202309748
crossref_primary_10_3390_cells11091587
crossref_primary_10_1007_s00018_022_04619_1
crossref_primary_10_3390_ijms231810232
crossref_primary_10_3389_fphar_2023_1293578
crossref_primary_10_1016_j_jcf_2023_05_003
crossref_primary_10_1016_j_coph_2022_102210
crossref_primary_10_1016_j_rmr_2025_01_001
crossref_primary_10_1016_j_heliyon_2023_e15756
crossref_primary_10_1183_13993003_02153_2022
Cites_doi 10.1073/pnas.0904709106
10.1016/j.jcf.2019.05.003
10.1056/NEJMoa043900
10.1007/978-1-61779-120-8_18
10.1126/science.1223012
10.1038/nature11130
10.1126/scitranslmed.3010525
10.1164/rccm.201810-1972OC
10.1164/rccm.201412-2230OC
10.1126/scitranslmed.aav3488
10.1126/science.1255825
10.1016/j.biocel.2014.03.011
10.1002/ppul.24530
10.1016/S0092-8674(00)81724-9
10.1172/JCI73469
10.1016/S0140-6736(08)61162-9
10.1101/cshperspect.a009753
10.1056/NEJMoa1105185
10.1021/acs.biomac.7b00809
10.1016/j.molmed.2007.05.001
10.1152/physrev.00039.2014
10.1101/cshperspect.a009597
10.1056/NEJMoa1701632
10.1183/13993003.01297-2018
10.1172/jci.insight.122695
10.1056/NEJMoa1807119
10.1183/13993003.02652-2017
10.1371/journal.pone.0087681
10.1164/rccm.201404-0670OC
10.1164/rccm.201802-0245OC
10.1038/s41467-017-00532-5
10.1172/JCI83922
ContentType Journal Article
Copyright Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
Copyright_xml – notice: Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1183/13993003.00185-2021
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3003
ExternalDocumentID PMC8859811
34172469
10_1183_13993003_00185_2021
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: P01 HL108808
– fundername: NIDDK NIH HHS
  grantid: P30 DK065988
GroupedDBID ---
.55
.GJ
18M
1OC
2WC
31~
3O-
53G
5GY
5RE
5VS
8-1
AADJU
AAFWJ
AAYXX
AAZMJ
ABCQX
ABJNI
ABOCM
ABSQV
ACEMG
ACGFO
ACPRK
ACXQS
ADBBV
ADDZX
ADMOG
ADYFA
AENEX
AFFNX
AFHIN
AFZJQ
AIZTS
AJAOE
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CAG
CITATION
COF
CS3
DIK
E3Z
EBS
EJD
F5P
F9R
GX1
H13
INIJC
J5H
KQ8
L7B
LH4
LW6
OK1
P2P
PQQKQ
R0Z
RHI
TER
TR2
W8F
WOQ
X7M
ZE2
ZGI
ZXP
~02
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c360t-e03dc50674f9c89bfe5c66862f7fa3463174a8064969c73096cde6c8404f2e63
ISSN 0903-1936
1399-3003
IngestDate Thu Aug 21 18:38:06 EDT 2025
Fri Jul 11 03:01:06 EDT 2025
Mon Jul 21 06:03:57 EDT 2025
Tue Jul 01 05:42:46 EDT 2025
Thu Apr 24 22:54:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c360t-e03dc50674f9c89bfe5c66862f7fa3463174a8064969c73096cde6c8404f2e63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4031-9521
PMID 34172469
PQID 2545597218
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8859811
proquest_miscellaneous_2545597218
pubmed_primary_34172469
crossref_citationtrail_10_1183_13993003_00185_2021
crossref_primary_10_1183_13993003_00185_2021
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-00
20220201
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-00
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The European respiratory journal
PublicationTitleAlternate Eur Respir J
PublicationYear 2022
References Ramsey (2024102102315534000_59.2.2100185.21) 2016; 112
2024102102315534000_59.2.2100185.18
2024102102315534000_59.2.2100185.16
2024102102315534000_59.2.2100185.15
2024102102315534000_59.2.2100185.14
2024102102315534000_59.2.2100185.13
2024102102315534000_59.2.2100185.12
2024102102315534000_59.2.2100185.11
2024102102315534000_59.2.2100185.33
2024102102315534000_59.2.2100185.10
2024102102315534000_59.2.2100185.32
2024102102315534000_59.2.2100185.31
2024102102315534000_59.2.2100185.30
2024102102315534000_59.2.2100185.9
2024102102315534000_59.2.2100185.7
2024102102315534000_59.2.2100185.8
2024102102315534000_59.2.2100185.5
Donaldson (2024102102315534000_59.2.2100185.25) 2018; 3
2024102102315534000_59.2.2100185.6
2024102102315534000_59.2.2100185.3
2024102102315534000_59.2.2100185.4
2024102102315534000_59.2.2100185.1
2024102102315534000_59.2.2100185.2
2024102102315534000_59.2.2100185.29
2024102102315534000_59.2.2100185.28
Chen (2024102102315534000_59.2.2100185.19) 2019; 200
2024102102315534000_59.2.2100185.27
2024102102315534000_59.2.2100185.26
2024102102315534000_59.2.2100185.24
2024102102315534000_59.2.2100185.23
Hao (2024102102315534000_59.2.2100185.17) 2020; 19
2024102102315534000_59.2.2100185.22
2024102102315534000_59.2.2100185.20
References_xml – ident: 2024102102315534000_59.2.2100185.14
  doi: 10.1073/pnas.0904709106
– volume: 19
  start-page: 34
  year: 2020
  ident: 2024102102315534000_59.2.2100185.17
  article-title: Inactivation of CFTR by CRISPR/Cas9 alters transcriptional regulation of inflammatory pathways and other networks
  publication-title: J Cyst Fibros
  doi: 10.1016/j.jcf.2019.05.003
– ident: 2024102102315534000_59.2.2100185.32
  doi: 10.1056/NEJMoa043900
– ident: 2024102102315534000_59.2.2100185.18
  doi: 10.1007/978-1-61779-120-8_18
– ident: 2024102102315534000_59.2.2100185.11
  doi: 10.1126/science.1223012
– ident: 2024102102315534000_59.2.2100185.24
  doi: 10.1038/nature11130
– ident: 2024102102315534000_59.2.2100185.23
  doi: 10.1126/scitranslmed.3010525
– volume: 200
  start-page: 220
  year: 2019
  ident: 2024102102315534000_59.2.2100185.19
  article-title: XBP1S regulates MUC5B in a promoter variant-dependent pathway in IPF airway epithelia
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201810-1972OC
– ident: 2024102102315534000_59.2.2100185.13
  doi: 10.1164/rccm.201412-2230OC
– ident: 2024102102315534000_59.2.2100185.27
  doi: 10.1126/scitranslmed.aav3488
– ident: 2024102102315534000_59.2.2100185.28
  doi: 10.1126/science.1255825
– volume: 112
  start-page: 54153
  year: 2016
  ident: 2024102102315534000_59.2.2100185.21
  article-title: Mucin agarose gel electrophoresis: Western blotting for high-molecular-weight glycoproteins
  publication-title: J Vis Exp
– ident: 2024102102315534000_59.2.2100185.4
  doi: 10.1016/j.biocel.2014.03.011
– ident: 2024102102315534000_59.2.2100185.1
  doi: 10.1002/ppul.24530
– ident: 2024102102315534000_59.2.2100185.30
  doi: 10.1016/S0092-8674(00)81724-9
– ident: 2024102102315534000_59.2.2100185.10
  doi: 10.1172/JCI73469
– ident: 2024102102315534000_59.2.2100185.6
  doi: 10.1016/S0140-6736(08)61162-9
– ident: 2024102102315534000_59.2.2100185.2
  doi: 10.1101/cshperspect.a009753
– ident: 2024102102315534000_59.2.2100185.15
  doi: 10.1056/NEJMoa1105185
– ident: 2024102102315534000_59.2.2100185.8
  doi: 10.1021/acs.biomac.7b00809
– ident: 2024102102315534000_59.2.2100185.9
  doi: 10.1016/j.molmed.2007.05.001
– ident: 2024102102315534000_59.2.2100185.3
  doi: 10.1152/physrev.00039.2014
– ident: 2024102102315534000_59.2.2100185.5
  doi: 10.1101/cshperspect.a009597
– ident: 2024102102315534000_59.2.2100185.20
  doi: 10.1056/NEJMoa1701632
– ident: 2024102102315534000_59.2.2100185.22
  doi: 10.1183/13993003.01297-2018
– volume: 3
  start-page: e122695
  year: 2018
  ident: 2024102102315534000_59.2.2100185.25
  article-title: Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.122695
– ident: 2024102102315534000_59.2.2100185.16
  doi: 10.1056/NEJMoa1807119
– ident: 2024102102315534000_59.2.2100185.33
  doi: 10.1183/13993003.02652-2017
– ident: 2024102102315534000_59.2.2100185.12
  doi: 10.1371/journal.pone.0087681
– ident: 2024102102315534000_59.2.2100185.31
  doi: 10.1164/rccm.201404-0670OC
– ident: 2024102102315534000_59.2.2100185.26
  doi: 10.1164/rccm.201802-0245OC
– ident: 2024102102315534000_59.2.2100185.29
  doi: 10.1038/s41467-017-00532-5
– ident: 2024102102315534000_59.2.2100185.7
  doi: 10.1172/JCI83922
SSID ssj0016431
Score 2.554577
Snippet Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2100185
SubjectTerms Bicarbonates - metabolism
Cystic Fibrosis - metabolism
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - metabolism
Humans
Ion Transport
Mucus - metabolism
Title Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration
URI https://www.ncbi.nlm.nih.gov/pubmed/34172469
https://www.proquest.com/docview/2545597218
https://pubmed.ncbi.nlm.nih.gov/PMC8859811
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkKa9IH5TBshIvIVAmjiO84gmpglUJKBIe4scx1aLaFJlyVD3uL-cu8T50W0g4CWq4sSJ8n217-zv7gh5lUWMpwI1T5Gfucz3IjeWoXYx5jOG6c83DGOH55_4yTf24TQ8nUwuR6qlukrfqIsb40r-B1U4B7hilOw_INt3CifgN-ALR0AYjn-Hca8SR3H4FlMuOwb83wKzjMhV-VNuHVyZtyFsR8eLL1j6Bit2YY0dzN6EEg5HprqEOaty1rWqz1CztUG5NbScr6Sz3GblgN_3gV79Sn452q8fv3gr5m2qHLbikrUugW39Ls_XpcTyLDY-KMNd8vnAQJlK23Ihh8VcDC4qznVThtax1cqt6tEuXoDf6_VCEN0OuGAguYHnBeMR2eYIXw2O8fWBXmDCCbwbb8b9JBECN9po6xH0m3WDPczVkc_aojBX8mt3TbfIbR9cDRwrP34edqLAYpvZbFXwzLc3PPGA7Hd97Bo31zyWq8LbkSWzuEvuWBeEvmv5dI9MdH6f7M-tyOIBKXpa0cLQlla0oxVtaUUbWlGkFUVa0YFWtKMV7WhFG1rRgVYUaEV7Wj0ki-P3i6MT19blcFXAvcrVXpCpEMwcZmIl4tToUHGMNDKRkQHjYJIyKcDWjXmsYAaJuco0V4J5zPiaB4_IXl7k-gmhkfGVTLNQc81YaiRWA8gMWJAm9gVXckr87nsmyuasx9IpP5LGdxVB0uGRNHgkiMeUvO5v2rQpW_58-csOqASGVvx8MtdFfZb44F2EmN1KTMnjFri-ww7xKYl2IO0vwLTtuy35atmkbxcijMVs9vS3fR6Sg-G_8ozsVWWtn4PpW6UvGm7-AptksCs
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+cystic+fibrosis+airway+cells+with+CFTR+modulators+reverses+aberrant+mucus+properties+via+hydration&rft.jtitle=The+European+respiratory+journal&rft.au=Morrison%2C+Cameron+B&rft.au=Shaffer%2C+Kendall+M&rft.au=Araba%2C+Kenza+C&rft.au=Markovetz%2C+Matthew+R&rft.date=2022-02-01&rft.eissn=1399-3003&rft.volume=59&rft.issue=2&rft_id=info:doi/10.1183%2F13993003.00185-2021&rft_id=info%3Apmid%2F34172469&rft.externalDocID=34172469
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0903-1936&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0903-1936&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0903-1936&client=summon